Travere Therapeutics, Inc.
NASDAQ:TVTXBiotechnology
+$0.65 today
- Market cap
- $4.82B
- Beta
- 1.14
- P/E (TTM)
- -235.0
- EPS (TTM)
- -$0.23
Volume 0.84M
Average 2.31M
TVTX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Travere Therapeutics, Inc.NASDAQ: TVTX
Retained Earnings · Q3 FY2026 · quarter ended Sep 2026
Retained earnings remains negative
Q3 FY2026 retained earnings was -$1.6B, compared with -$1.48B a year earlier.
Context
- Retained earnings amounted to 188.3% of total assets at the end of Q3 FY2026, down 85.7 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -8.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (1.47B) USD
- Year-over-year change
- -1.8%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.47B) | -1.8% |
| FY2024 | 2024-12-31 | (1.45B) | -28.6% |
| FY2023 | 2023-12-31 | (1.13B) | -11.0% |
| FY2022 | 2022-12-31 | (1.01B) | -32.4% |
| FY2021 | 2021-12-31 | (765.97M) | — |
Retained Earnings vs competitors
How TVTX compares with its peers on the latest reported figures
- TVTX's Sep 2026 retained earnings of -$1.6B is the lowest of the 5 companies compared; the peer median is -$625.67M.
- Its year-over-year change of -8.2% is the 3rd highest of 5, against a peer median of -18.6%.
- Retained earnings amounts to 188.3% of total assets for TVTX, versus a peer median of 116.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$281.46M | +3.9% | — | 57.5% | |
| Mar 2026 | -$513.76M | -31.3% | — | 122.4% | |
| Jun 2026 | -$737.58M | -90.1% | — | 110.4% | |
| Mar 2026 | -$1.29B | -5.9% | — | 440.6% | |
| Sep 2026 | -$1.6B | -8.2% | — | 188.3% | |
| Peer median (excluding TVTX) | -$625.67M | -18.6% | — | 116.4% | |
Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 165.75M | 61.69M | 58.18M | 58.54M | 93.04M |
| Short-term Investments | 387.13M | 388.56M | 508.68M | 312.17M | 229.76M |
| Net Receivables | 15.91M | 16.65M | 21.18M | 27.12M | 80.13M |
| Inventory | 7.31M | 4.52M | 9.41M | 6.2M | 5.88M |
| Other Current Assets | 247K | 15.02M | 19.34M | 12.69M | 28.76M |
| Total Current Assets | 582.83M | 486.44M | 616.78M | 416.7M | 437.57M |
| Property, Plant & Equipment (Net) | 34.3M | 30.05M | 25.54M | 19.63M | 14.6M |
| Goodwill | 900K | 800K | 753K | 753K | 0 |
| Intangible Assets | 147.5M | 96.32M | 103.69M | 103.22M | 113.12M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 11.07M | 59.03M | 42.16M | 53.82M | 39.16M |
| Total Non-current Assets | 193.77M | 186.2M | 172.14M | 177.42M | 166.87M |
| Total Assets | 776.63M | 672.59M | 788.91M | 594.13M | 605.19M |
| Account Payables | 15.14M | 17.29M | 41.68M | 23.53M | 24.8M |
| Short-term Debt | 0 | 0 | 0 | 68.68M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 16.27M | 11.98M | 7.1M | 2.82M | 0 |
| Other Current Liabilities | 39.59M | 47.99M | 94.32M | 49.46M | 44.71M |
| Total Current Liabilities | 124.09M | 142.16M | 177.91M | 200.75M | 159.9M |
| Long-term Debt | 226.58M | 375.55M | 377.26M | 310.31M | 311.72M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 20.38M | 10.93M | 1.84M | 0 | 0 |
| Other Non-current Liabilities | 71.98M | 73.59M | 8.49M | 6.8M | 7.6M |
| Total Non-current Liabilities | 350.43M | 487.57M | 410.2M | 334.3M | 330.46M |
| Total Liabilities | 474.52M | 629.73M | 588.1M | 535.05M | 490.36M |
| Common Stock | 6K | 6K | 7K | 9K | 9K |
| Retained Earnings | (765.97M) | (1.01B) | (1.13B) | (1.45B) | (1.47B) |
| Accumulated OCI | (562K) | (2.91M) | (1.46M) | (80K) | (1.19M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 302.11M | 42.85M | 200.81M | 59.08M | 114.83M |
| Total Debt | 261.99M | 407.49M | 404.78M | 401.58M | 328.73M |
| Net Debt | 96.23M | 345.8M | 346.61M | 343.05M | 235.7M |
Travere Therapeutics, Inc.
NASDAQ:TVTX
Intrinsic Alpha fair value
Locked
Current Price
$50.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.